COVID-19 Vaccine: A comprehensive status report
- PMID: 32800805
- PMCID: PMC7423510
- DOI: 10.1016/j.virusres.2020.198114
COVID-19 Vaccine: A comprehensive status report
Abstract
The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life.
Keywords: COVID-19; Clinical Trials; Convalescent Plasma Therapy; Monoclonal Antibodies; SARS-CoV-2; Vaccine.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
The author(s) declare that there are no conflicts of interest.
Figures
Similar articles
-
Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.Virus Res. 2020 Oct 15;288:198141. doi: 10.1016/j.virusres.2020.198141. Epub 2020 Aug 23. Virus Res. 2020. PMID: 32846196 Free PMC article. Review.
-
A systematic review of SARS-CoV-2 vaccine candidates.Signal Transduct Target Ther. 2020 Oct 13;5(1):237. doi: 10.1038/s41392-020-00352-y. Signal Transduct Target Ther. 2020. PMID: 33051445 Free PMC article.
-
Immunological considerations for COVID-19 vaccine strategies.Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4. Nat Rev Immunol. 2020. PMID: 32887954 Free PMC article. Review.
-
Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.Vaccine. 2020 Nov 10;38(48):7612-7628. doi: 10.1016/j.vaccine.2020.10.016. Epub 2020 Oct 9. Vaccine. 2020. PMID: 33082015 Free PMC article.
-
Keeping track of the SARS-CoV-2 vaccine pipeline.Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1. Nat Rev Immunol. 2020. PMID: 32989290 Free PMC article.
Cited by
-
SARS-CoV-2 vaccines: Lights and shadows.Eur J Intern Med. 2021 Jun;88:1-8. doi: 10.1016/j.ejim.2021.04.019. Epub 2021 Apr 30. Eur J Intern Med. 2021. PMID: 33966930 Free PMC article. Review.
-
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.Respir Med. 2021 Apr-May;180:106355. doi: 10.1016/j.rmed.2021.106355. Epub 2021 Mar 6. Respir Med. 2021. PMID: 33721697 Free PMC article. Review.
-
Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta Pharm Sin B. 2022 Nov 21;13(7):2897-925. doi: 10.1016/j.apsb.2022.11.022. Online ahead of print. Acta Pharm Sin B. 2022. PMID: 36438851 Free PMC article. Review.
-
Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view.Life Sci. 2021 Aug 1;278:119580. doi: 10.1016/j.lfs.2021.119580. Epub 2021 May 12. Life Sci. 2021. PMID: 33991549 Free PMC article. Review.
-
COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews.Front Public Health. 2022 Nov 15;10:1072137. doi: 10.3389/fpubh.2022.1072137. eCollection 2022. Front Public Health. 2022. PMID: 36457318 Free PMC article.
References
-
- Ahn J.Y., Sohn Y., Lee S.H., Cho Y., Hyun J.H., Baek Y.J., Jeong S.J., Kim J.H., Ku N.S., Yeom J.S., Roh J., Ahn M.Y., Chin B.S., Kim Y.S., Lee H., Yong D., Kim H.O., Kim S., Choi J.Y. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14, April) doi: 10.3346/jkms.2020.35.e149. - DOI - PMC - PubMed
-
- Anon . 2020. Countries where COVID-19 has spread. www.worldometers.info. [Online] July 30, 2020. [Cited: July 31, 2020.] https://www.worldometers.info/coronavirus/countries-where-coronavirus-ha....
-
- Anon . 2020. Coronavirus Resource Center. https://coronavirus.jhu.edu/. [Online] Johns Hopkins University. [Cited: August 05, 2020.] https://coronavirus.jhu.edu/map.html.
-
- Anon . 2020. COVID-19 Treatment and Vaccine Tracker.https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7... https://airtable.com/. [Online] Milken Institute.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous